Compare Costco Wholesale Corporation (COST) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Costco Wholesale Corporation vs TG Therapeutics Inc — how do they compare? Costco Wholesale Corporation trades at $924.3 (market cap $408.78B), while TG Therapeutics Inc trades at $55.31 (market cap $8.41B). The key difference: Costco Wholesale Corporation is far larger — about 48.6× TG Therapeutics Inc's market cap, and Costco Wholesale Corporation pays a 0.64% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| COST | TGTX | |
|---|---|---|
Market Cap | $408.78B | $8.41B |
Sector | Consumer Staples | Health |
52-Week High | $1.09K | $59.06 |
52-Week Low | $849.63 | $26.39 |
Enterprise Value | $396.92B | $8.65B |
Dividend Yield | 0.64% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Costco (COST) trades at $923.9, down 0.27% with bearish technical signals but strong fundamentals. The stock shows consistent revenue growth, reaching $275.24B in 2025 with net income of $8.10B. Recent March sales surged 11.3% year-over-year to $28.41B, indicating robust business momentum. Analyst consensus remains strongly bullish with 65.5% buy ratings and a $1,120 price target, though valuation metrics appear elevated with P/E at 46.37.
The investment case balances premium valuation against exceptional operational execution. Membership fee increases and expanding warehouse network drive profitability, but high P/E ratio requires sustained growth. Key risks include competitive pressure and economic sensitivity, while institutional accumulation supports long-term confidence.
TG Therapeutics (TGTX) trades at $55.01, down 3.69% today, with a bullish technical signal from moving averages and a consensus analyst rating of 'Buy' from 11 of 13 analysts. The company reported strong revenue growth to $616.29 million in 2025 and a net income of $447.18 million, though recent quarterly EPS misses and negative operating cash flow of -$24.77 million highlight volatility. Positive news includes Phase II trials for Briumvi in schizophrenia and Phase I success in myasthenia gravis, driving investor optimism.
Outlook: TGTX offers growth potential through pipeline expansion and robust sales guidance, but faces risks from clinical trial outcomes, cash flow challenges, and high valuation multiples. The stock's 70% year-to-date gain reflects high expectations, requiring careful monitoring of execution against earnings forecasts and regulatory milestones.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Costco Wholesale Corporation
The leading warehouse club, Costco has 815 stores worldwide (at the end of fiscal 2021), with most sales derived in the United States (72%) and Canada (14%). It sells memberships that allow customers to shop in its warehouses, which feature low prices on a limited product assortment. Costco mainly caters to individual shoppers, but roughly 20% of paid members carry business memberships. Food and sundries accounted for 40% of fiscal 2021 sales, with non-food merchandise 29%, warehouse ancillary and other businesses (such as fuel and pharmacy) nearly 17%, and fresh food 14%. Costco's warehouses average around 146,000 square feet
Read more on COST →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
